BBCMF (Lir Life Sciences) NonCurrent Deferred Revenue: $0.00 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BBCMF Lir Life Sciences Corp BBCMF
12 GF Score
Price $0.20
View Full Analysis

What is Lir Life Sciences NonCurrent Deferred Revenue?

Lir Life Sciences BBCMF +300.00% 12 NonCurrent Deferred Revenue is $0.00 Mil as of Jan. 2026. GuruFocus rates BBCMF with a GF Score™ of 12/100.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Lir Life Sciences's non-current deferred revenue for the quarter that ended in Jan. 2026 was $0.00 Mil.

Lir Life Sciences NonCurrent Deferred Revenue Related Terms

Lir Life Sciences NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences NonCurrent Deferred Revenue Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
NonCurrent Deferred Revenue
0.00 0.00

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
NonCurrent Deferred Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BBCMF
12GF Score
Lir Life Sciences Corp BBCMF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0.00 Mil mean?
Lir Life Sciences (BBCMF) has a NonCurrent Deferred Revenue of $0.00 Mil as of Jan. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Lir Life Sciences and its competitors.
Is Lir Life Sciences' NonCurrent Deferred Revenue too high?
Lir Life Sciences' current NonCurrent Deferred Revenue is $0.00 Mil. Overall, Lir Life Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' NonCurrent Deferred Revenue compare to VRTX and REGN?
Lir Life Sciences' NonCurrent Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Biotechnology company?
A good NonCurrent Deferred Revenue depends on the Biotechnology industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current NonCurrent Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current NonCurrent Deferred Revenue of $0.00 Mil. The current NonCurrent Deferred Revenue is $0.00 Mil. Lir Life Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current NonCurrent Deferred Revenue is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
12GF Score

Get the complete analysis for BBCMF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price